CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 28 enrolled
Drug / intervention
RSV A Memphis 37biological
Likely dose
RSV A Memphis 37 1mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03728413
NCT03728413N/ACompleted

The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus

Imperial College London·interventional·Posted Nov 2, 2018·Updated Jan 26, 2026

In Brief

A clinical study evaluating RSV A Memphis 37 for RSV Infection. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This study will for the first time systematically investigate the immune responses in an elderly cohort challenged with a well-defined RSV inoculum. With a global aging population and continuing difficulties in generating vaccines that can reliably induce protective immunity in the elderly, these data will indicate the targets at which development of vaccines against RSV and other infections should be directed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRSV Infection
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedNov 2, 2018
Enrollment StartNov 12, 2018
Primary CompletionMay 4, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 7.7 years ago

Interventions

RSV A Memphis 37biological

Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact. Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment.